 <h1>Fondaparinux Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to fondaparinux: subcutaneous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Subcutaneous route (Solution)</p><p>Epidural or spinal hematomas, which may result in long-term or permanent paralysis, can occur in patients who are anticoagulated with low molecular weight heparins, heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture. Use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis (eg, NSAIDs, platelet inhibitors, or other anticoagulants), history of traumatic or repeated epidural or spinal puncture, spinal deformity, or spinal surgery may increase the risk of developing these hematomas. Monitor patients frequently for neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, fondaparinux may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking fondaparinux:</p><p>
<i>More common</i>
</p><ul>
<li>Pale skin</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bladder pain</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>chills</li>
<li>collection of blood under the skin</li>
<li>confusion</li>
<li>convulsions</li>
<li>cough</li>
<li>decreased or cloudy urine</li>
<li>deep, dark purple bruise</li>
<li>difficult, burning, or painful urination</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fainting or lightheadedness when getting up from a lying or sitting position</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>itching, pain, redness, or swelling at the injection site</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle pain or cramps</li>
<li>nausea or vomiting</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>pinpoint red spots on the skin</li>
<li>red, tender, or oozing skin at incision</li>
<li>shortness of breath</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>sudden sweating</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Back pain</li>
<li>bowel or bladder dysfunction</li>
<li>difficulty with swallowing</li>
<li>fast heartbeat</li>
<li>hives, itching, or skin rash</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>leg weakness</li>
<li>numbness</li>
<li>paralysis</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>tightness in the chest</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking fondaparinux:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Abdominal or stomach pain or swelling</li>
<li>bruising or purple areas on the skin</li>
<li>coughing up blood</li>
<li>decreased alertness</li>
<li>headache</li>
<li>joint pain or swelling</li>
<li>nosebleeds</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of fondaparinux may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty having a bowel movement</li>
<li>swelling</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>diarrhea</li>
<li>heartburn</li>
<li>indigestion</li>
<li>pain</li>
<li>skin blisters</li>
<li>stomach discomfort, upset, or pain</li>
<li>tightness in the chest</li>
<li>unusual changes to site of surgery</li>
<li>wound drainage, increased</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fondaparinux: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were bleeding events.</p>
<p>The most serious adverse events were bleeding complications and thrombocytopenia.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The majority of major bleeding events occurred during the first 4 days after surgery.  Major bleeding incidence increased in patients weighing less than 50 kg and in patients with impaired renal function.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Anemia (19.6%)</p>
<p><b>Common</b> (1% to 10%): Post-operative hemorrhage, major bleeding, minor bleeding, moderate thrombocytopenia, non-fatal major bleeding at surgical site, overt bleeding associated with a bleeding index of 2 or greater, prothrombin decreased, other clinically overt bleeding, bleeding</p>
<p><b>Uncommon</b> (0.1% to 1%): Reoperation due to bleeding, non-fatal major bleeding at non-surgical site, severe thrombocytopenia, fatal bleeding, intracranial bleeding, thrombocythemia, abnormal platelets, coagulation disorder </p>
<p><b>Very rare</b> (less than 0.01%): Hypertensive encephalopathy with intracranial bleeding, minor gastrointestinal bleeding</p>
<p><b>Postmarketing reports</b>: Thrombocytopenia with thrombosis, aPTT elevation, intracerebral bleeding, retroperitoneal bleeding<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (13.6%)</p>
<p><b>Common</b> (1% to 10%): Edema, post-operative wound infection, wound drainage increased, surgical site reaction, pain, chest pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Edema peripheral, wound secretion</p>
<p><b>Rare</b> (less than 0.1%): Hot flushes<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (11.3%)</p>
<p><b>Common</b> (1% to 10%): Constipation, vomiting, diarrhea, dyspepsia, abdominal pain</p>
<p><b>Rare</b> (less than 0.1%): Gastritis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Hematoma, bruising</p>
<p><b>Rare</b> (less than 0.1%): Injection site reaction</p>
<p><b>Frequency not reported</b>: Local irritation (injection site bleeding, rash, pruritus)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increases in ALT, increases in AST</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatic function abnormal, hepatic enzymes increased</p>
<p><b>Rare</b> (less than 0.1%): Bilirubinemia</p>
<p><b>Frequency not reported</b>: Increases in bilirubin<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypotension, hypertension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, purpura, bullous eruption (includes localized blister)</p>
<p><b>Uncommon</b> (0.1% to 1%): Pruritus</p>
<p><b>Rare</b> (less than 0.1%): Flushing<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness </p>
<p><b>Rare</b> (less than 0.1%): Somnolence, vertigo, fatigue, syncope</p>
<p><b>Postmarketing reports</b>: Spinal or epidural hematoma<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, urinary retention</p>
<p><b>Rare</b> (less than 0.1%): Edema genital<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Leg pain, back pain<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, confusion</p>
<p><b>Uncommon</b> (0.1% to 1%): Anxiety<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, coughing, epistaxis</p>
<p><b>Rare</b> (less than 0.1%): Dyspnea<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Allergic reaction</p>
<p><b>Very rare</b> (less than 0.01%): Angioedema, anaphylactoid/anaphylactic reaction</p>
<p><b>Postmarketing reports</b>: Serious allergic reactions<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Arixtra (fondaparinux)." Organon, West Orange, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Warkentin TE,  Maurer BT,  Aster RH "Heparin-induced thrombocytopenia associated with fondaparinux." N Engl J Med 356 (2007): 2653-5; discussion 2653-5</p><p id="ref_5">5. Savi P,  Chong BH,  Greinacher A, et al. "Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies. A blinded comparative multicenter study with unfractionated heparin." Blood 105 (2005): 139-41</p></div>
<div class="more-resources" id="moreResources">
<h2>More about fondaparinux</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>7 Reviews</li>
<li>Drug class: factor Xa inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fondaparinux Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Arixtra</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Deep Vein Thrombosis</li>
<li>Deep Vein Thrombosis Prophylaxis after Abdominal Surgery</li>
<li>Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery</li>
<li>Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery</li>
<li data-more-config-id="list-data-resources-conditions">... +3 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fondaparinux: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were bleeding events.</p><p>The most serious adverse events were bleeding complications and thrombocytopenia.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>The majority of major bleeding events occurred during the first 4 days after surgery.  Major bleeding incidence increased in patients weighing less than 50 kg and in patients with impaired renal function.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Anemia (19.6%)</p><p><b>Common</b> (1% to 10%): Post-operative hemorrhage, major bleeding, minor bleeding, moderate thrombocytopenia, non-fatal major bleeding at surgical site, overt bleeding associated with a bleeding index of 2 or greater, prothrombin decreased, other clinically overt bleeding, bleeding</p><p><b>Uncommon</b> (0.1% to 1%): Reoperation due to bleeding, non-fatal major bleeding at non-surgical site, severe thrombocytopenia, fatal bleeding, intracranial bleeding, thrombocythemia, abnormal platelets, coagulation disorder </p><p><b>Very rare</b> (less than 0.01%): Hypertensive encephalopathy with intracranial bleeding, minor gastrointestinal bleeding</p><p><b>Postmarketing reports</b>: Thrombocytopenia with thrombosis, aPTT elevation, intracerebral bleeding, retroperitoneal bleeding<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (13.6%)</p><p><b>Common</b> (1% to 10%): Edema, post-operative wound infection, wound drainage increased, surgical site reaction, pain, chest pain</p><p><b>Uncommon</b> (0.1% to 1%): Edema peripheral, wound secretion</p><p><b>Rare</b> (less than 0.1%): Hot flushes<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (11.3%)</p><p><b>Common</b> (1% to 10%): Constipation, vomiting, diarrhea, dyspepsia, abdominal pain</p><p><b>Rare</b> (less than 0.1%): Gastritis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Hematoma, bruising</p><p><b>Rare</b> (less than 0.1%): Injection site reaction</p><p><b>Frequency not reported</b>: Local irritation (injection site bleeding, rash, pruritus)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increases in ALT, increases in AST</p><p><b>Uncommon</b> (0.1% to 1%): Hepatic function abnormal, hepatic enzymes increased</p><p><b>Rare</b> (less than 0.1%): Bilirubinemia</p><p><b>Frequency not reported</b>: Increases in bilirubin<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypotension, hypertension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, purpura, bullous eruption (includes localized blister)</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus</p><p><b>Rare</b> (less than 0.1%): Flushing<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness </p><p><b>Rare</b> (less than 0.1%): Somnolence, vertigo, fatigue, syncope</p><p><b>Postmarketing reports</b>: Spinal or epidural hematoma<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, urinary retention</p><p><b>Rare</b> (less than 0.1%): Edema genital<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Leg pain, back pain<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, confusion</p><p><b>Uncommon</b> (0.1% to 1%): Anxiety<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, coughing, epistaxis</p><p><b>Rare</b> (less than 0.1%): Dyspnea<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Allergic reaction</p><p><b>Very rare</b> (less than 0.01%): Angioedema, anaphylactoid/anaphylactic reaction</p><p><b>Postmarketing reports</b>: Serious allergic reactions<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Arixtra (fondaparinux)." Organon, West Orange, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Warkentin TE,  Maurer BT,  Aster RH "Heparin-induced thrombocytopenia associated with fondaparinux." N Engl J Med 356 (2007): 2653-5; discussion 2653-5</p><p id="ref_5">5. Savi P,  Chong BH,  Greinacher A, et al. "Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies. A blinded comparative multicenter study with unfractionated heparin." Blood 105 (2005): 139-41</p><h2>More about fondaparinux</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>7 Reviews</li>
<li>Drug class: factor Xa inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fondaparinux Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Deep Vein Thrombosis</li>
<li>Deep Vein Thrombosis Prophylaxis after Abdominal Surgery</li>
<li>Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery</li>
<li>Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery</li>
<li data-more-config-id="list-data-resources-conditions">... +3 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>